Alembic Pharmaceuticals gets USFDA approval for Fluoxetine Hydrochloride Tablets

07 Apr 2017 Evaluate

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fluoxetine Hydrochloride Tablets, 10 mg and 20mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Prozac Tablets, 10 mg and 20mg, of Eli Lilly and Company.

Fluoxetine Hydrochloride Tablets are indicated for the treatment of Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD) in adult and pediatric patients. Fluoxetine Tablets are also indicated for treatment of binge eating and vomiting behaviour in moderate to severe Bulimia Nervosa and acute treatment of Panic Disorder, in adult patients.

Fluoxetine Hydrochloride Tablets have an estimated market size of $120 million for twelve months ending December 2015. Alembic now has a total of 53 ANDA approvals (47 final approvals and 6 tentative approvals) from the USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

Alembic Pharma Share Price

775.30 -13.90 (-1.76%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×